CN Patent

CN112010809A — 奥拉帕尼的晶型i及其制备方法

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2020-12-01 · 5y expired

What this patent protects

本发明涉及奥拉帕尼的晶型I及其制备方法。具体的，本发明提供的晶型I，其特征在于，其X射线粉末衍射图在2theta值为6.4°±0.2°、12.7°±0.2°、15.1°±0.2°处具有特征峰。本发明提供的晶型I稳定性更好，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

本发明涉及奥拉帕尼的晶型I及其制备方法。具体的，本发明提供的晶型I，其特征在于，其X射线粉末衍射图在2theta值为6.4°±0.2°、12.7°±0.2°、15.1°±0.2°处具有特征峰。本发明提供的晶型I稳定性更好，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN112010809A
Jurisdiction
CN
Classification
—
Expires
2020-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.